|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM342851802 |
| 003 |
DE-627 |
| 005 |
20240909232211.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.109068
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1528.xml
|
| 035 |
|
|
|a (DE-627)NLM342851802
|
| 035 |
|
|
|a (NLM)35764258
|
| 035 |
|
|
|a (PII)S1521-6616(22)00149-8
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Scordio, Mirko
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 09.08.2022
|
| 500 |
|
|
|a Date Revised 09.09.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2022 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a The presence of anti-IFN neutralizing antibodies (NAB) has been reported in critically ill COVID-19 patients. We found that 87.5% (7/8) of HIV-1 patients co-infected with SARS-CoV-2 had serum anti-IFN-I NAB against IFN-α subtypes, IFN-β and/or IFN-ω. Anti-IFN-I NAB were also detected in oropharyngeal samples. Patients with NAB were males, and those with high serum anti-IFN-α/ω NAB titer had severe illness and exhibited reduction in the expression of IFN-stimulated genes. Thus, high titer of anti-IFN-α/ω NAB may contribute to the greater severity of COVID-19 in HIV-1 infected patients
|
| 650 |
|
4 |
|a Letter
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a HIV-1
|
| 650 |
|
4 |
|a HIV-1 and SARS-CoV-2 co-infection
|
| 650 |
|
4 |
|a ISGs
|
| 650 |
|
4 |
|a Interferon
|
| 650 |
|
4 |
|a Neutralizing antibodies
|
| 650 |
|
4 |
|a SARS-CoV-2
|
| 650 |
|
7 |
|a Antibodies, Neutralizing
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Viral
|2 NLM
|
| 650 |
|
7 |
|a Interferon Type I
|2 NLM
|
| 650 |
|
7 |
|a Interferon-alpha
|2 NLM
|
| 700 |
1 |
|
|a Frasca, Federica
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Santinelli, Letizia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sorrentino, Leonardo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pierangeli, Alessandra
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Turriziani, Ombretta
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mastroianni, Claudio M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Antonelli, Guido
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Viscidi, Raphael P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a d'Ettorre, Gabriella
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Scagnolari, Carolina
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 241(2022) vom: 05. Aug., Seite 109068
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:241
|g year:2022
|g day:05
|g month:08
|g pages:109068
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.109068
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 241
|j 2022
|b 05
|c 08
|h 109068
|